This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
« Back
Page 1 of 556
Article

Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

09:18AM 04/17/14

Article

The Recent Performance of 'Baker Brother Biotech Stocks' is Awful

By Adam Feuerstein

Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.

12:23PM 04/15/14

Article

FDA Approves Novartis' ALK Inhibitor! Maybe...Really Soon?

By Adam Feuerstein

Someone at Novartis screwed up today by sending out a mass email announcing the FDA approval of a new lung cancer drug ceritinib. Brand name: Zykadia. The only problem is FDA hasn't announced the approval of Zykadia yet.

03:07PM 04/11/14

Article

Oh Biotech, You Are a Cruel Bitch

By Adam Feuerstein

Wednesday's mini rally was a head fake, leading to more selling Thursday.

01:09PM 04/10/14

Article

MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO

By Adam Feuerstein

Dance Biopharma is developing a device which sends vaporized insulin liquid into a patient's lungs.

11:52AM 04/10/14

Article

When is a Warrant Not a Warrant? When Northwest Bio is Raising Money.

By Adam Feuerstein

An explanation of Northwest Bio's "up to" $32 million financing deal.

10:24AM 04/10/14

Article

Celgene Higher on Revlimid Patent Case Document Release

By Adam Feuerstein

Documents pertaining to an upcoming pre-trial "Markman" hearing were made public which appear to favor Celgene over Natco, the generic drugmaker challenging certain Revlimid patents, according to an analyst.

11:50AM 04/09/14

Article

Sarepta Therapeutics on Cusp of Huge Eteplirsen News

By Adam Feuerstein

Sarepta executives met again with FDA officials in March to nail down a regulatory path for the Duchenne muscular dystrophy drug eteplirsen. The company has promised to update investors about the outcome of the FDA meeting, but without saying exactly when.

02:34PM 04/08/14

Article

Healthcare Investors Suffering Losses While Drug-Pricing War Rages

By Adam Feuerstein

The latest salvo was lobbed Tuesday by pharmacy benefits manager Express Scripts against Gilead Sciences and its $1,000-per-day hepatitis C pill Sovaldi. Express Scripts says the U.S. healthcare system can't afford Sovaldi so it wants to form a coalition of private employers, insurance companies and the government focused on fair drug pricing. But first, Express wants Gilead to cut the price of Sovaldi or be frozen out when competing hepatitis C therapies are approved later this year and next, according to a Bloomberg report.

11:23AM 04/08/14

Article

Alkermes Will Seek U.S. Approval for Once-Monthly Schizophrenia Treatment

By Adam Feuerstein

If approved next year, Alkermes' aripiprazole lauroxil will compete against several other long-acting antipsychotics, including a similar once-monthly injectable aripiprazole approved last year and sold by Otuska and Lundbeck. But the schizophrenia treatment market (oral and injectable drugs) is big and growing -- more than $11 billion in the U.S. last year and $20 billion-plus worldwide. Oral versions of aripiprazole, sold under the brand name Abilify, generated $6.5 billion in sales last year.

09:11AM 04/08/14

« Back
Page 1 of 556

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,501.65 0.00 0.00%
S&P 500 1,878.61 +3.22 0.17%
NASDAQ 4,148.3380 +21.3710 0.52%

Brokerage Partners

Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs